Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Calidi Biotherapeutics Inc. (CLDI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: CLDI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $120
1 Year Target Price $120
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.02% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.46M USD | Price to earnings Ratio 4.06 | 1Y Target Price 120 |
Price to earnings Ratio 4.06 | 1Y Target Price 120 | ||
Volume (30-day avg) 1 | Beta 1.08 | 52 Weeks Range 1.10 - 22.30 | Updated Date 12/14/2025 |
52 Weeks Range 1.10 - 22.30 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -119.65% | Return on Equity (TTM) - |
Valuation
Trailing PE 4.06 | Forward PE - | Enterprise Value 3397872 | Price to Sales(TTM) 50.83 |
Enterprise Value 3397872 | Price to Sales(TTM) 50.83 | ||
Enterprise Value to Revenue 49.42 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 7167721 | Shares Floating 6111761 |
Shares Outstanding 7167721 | Shares Floating 6111761 | ||
Percent Insiders 15.44 | Percent Institutions 3.27 |
About Calidi Biotherapeutics Inc.
Exchange NYSE MKT | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-11-01 | CEO & Director Dr. Eric E. Poma Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.calidibio.com |
Full time employees 28 | Website https://www.calidibio.com | ||
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.